Table 4.
Adjusted risk of chronic kidney disease development among people living with HIV using Fine and Gray competing risks regression.
| Overall | Genotyped | Patient Reported Outcomes Cohort | Genotyped and Patient Reported Outcomes | |
|---|---|---|---|---|
| N=33,998 | N=7,462 | N=15,671 | N=5,344 | |
| aHR (95% CI)a | aHR (95% CI)a | aHR (95% CI)a | aHR (95% CI)a | |
| Demographics | ||||
| Female sex | 1·63 (1·50-1·78) | 1·79 (1·47-2·18) | 1·60 (1·26-2·04) | 1·60 (1·33-1·92) |
| Age at study entry | 1·07 (1·06-1·07) | 1·07 (1·06-1·08) | 1·07 (1·06-1·08) | 1·07 (1·06-1·08) |
| Black race | 0·79 (0·73-0·86) | 0·73 (0·54-0·99) | 0·58 (0·49-0·69) | 0·64 (0·41-1·00) |
| Baseline creatinine | 1·07 (1·05-1·08) | 1·39 (1·34-1·44) | 1·44 (1·37-1·52) | 1·41 (1·31-1·51) |
| APOL1 risk | – | 1·56 (1·15-2·14) | – | 1·64 (1·18-2·28) |
| African ancestry | – | 0·76 (0·48-1·22) | – | 0·83 (0·48-1·41) |
| Comorbid Conditions | ||||
| HCV infection | 1·11 (1·02-1·21) | – | – | – |
| HBV infection | 1·43 (1·25-1·63) | – | – | – |
| Diabetes | 1·98 (1·81-2·16) | 1·50 (1·25-1·79) | 1·37 (1·16-1·63) | 1·36 (1·16-1·59) |
| Hypertension | 1·93 (1·75-2·12) | 1·65 (1·49-1·79) | 1·60 (1·44-1·78) | 1·58 (1·32-1·90) |
| ART Naïve | 0·86 (0·79-1·07) | – | – | – |
| Log Viral Copy-years | 1·06 (1·04-1·07) | 1·05 (1·02-1·07) | 1·06 (1·03-1·08) | 1·07 (1·03-1·10) |
| ART duration, yrs. | 0·98 (0·96-0·99) | – | – | – |
| PI duration, yrs. | 1·02 (0·999-1·05) | – | – | – |
| Tenofovir duration, yrs. | – | 1·05 (0·998-1·11) | – | – |
| INSTI duration, yrs. | 1·10 (1·06-1·13) | 1·11 (1·05-1·17) | 1·12 (1·08-1·15) | 1·11 (1·03-1·20) |
| Indinavir duration, yrs. | – | 0·93 (0·86-1·00) | 0·86 (0·80-0·93) | – |
| CD4 < 200 cells/mL | 1·33 (1·23-1·44) | 1·14 (1·04-1·25) | 1·14 (1·03-1·27) | 1·18 (1·02-1·37) |
| High-risk alcohol use | – | – | 0·60 (0·46-0·79) | 0·64 (0·50-0·81) |
| Methamphetamine use | – | – | – | 0·87 (0·73-1·04) |
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; HCV, Hepatitis C virus; HBV, Hepatitis B virus; ART: antiretroviral therapy; VCY: viral copy-years.
a
Bold indicates significance at p<0.05.